莫西沙星治疗中重度老年社区获得性肺炎的临床研究

Clinical Study of Moxifloxacin in Treatment of Elderly Patients with Community Acquired Pneumonia

目的:评价莫西沙星治疗老年中重度社区获得性肺炎的临床疗效和安全性。方法:两组入选117例,莫西沙星治疗组59例,头孢曲松对照组58例,随机对照研究治疗老年中重度社区获得性肺炎的情况。结果:治疗组和对照组总有效率分别为88.14%和65.52%(P<0.05),治愈率分别为49.15%和37.93%(P<0.05),细菌清除率分别为84.09%和51.43%(P<0.05),不良反应发生率分别为8.47%和6.90%(P>0.05)。结论:莫西沙星治疗老年中重度社区获得性肺炎有效安全。

Objective： To evaluate the clinical efficacy and safety of moxifloxacin in the treatment of elderly patients with moderate to severe community acquired pneumonia. Methods： Elderly patients with moderate to severe community acquired pneumonia were treated with moxifloxacin or ceftriaxone sodium in a randomized controlled study. Results： A total of 117 patients were enrolled in this study, 59 patients in moxifloxacin group ,58 patients in ceftriaxone sodium group. The cure rates and the effective rates of moxifloxacin group and ceftriaxone sodium group were 49.15 %, 37.93 % （P 〈 0.05 ） and 88.14%, 65.52% （P 〈0.05） respectively. The rates of adverse reaction in the two groups were 8.47% and 6.90% （P 〉0.05） respectively. Conclusion：Moxifloxacin is effective and safe for the treatment of elderly patients with moderate to severe community acquired pneumonia.